The Department's report High Quality Care for All: NHS Next Stage Review Final Report (CM7432) states that, from 2009, the National Institute for Health and Clinical Excellence (NICE) will expand the number and reach of national quality standards either by selecting the best available standards, including the adoption of the relevant parts of national service frameworks or by filling in gaps. We are taking forward work on this proposal with NICE. NICE will need to work with a range of stakeholders as it develops national quality standards.
The information is in the following table.
Topic Work programme Published/ongoing Date of marketing authorisation1 Referral date2 Date of final NICE guidance Start of NICE appraisal3 Xolair (omalizumab) for uncontrolled asthma 8 Published October 2005 April 2003 November 2007 November 2006 Remicade (infliximab) for psoriasis 8 Published September 2005 April 2003 January 2008 March 2007 Natrecor (nesiritide), Heart failure (acute decompensated) 9 Ongoing n/a October 2003 n/a October 2003 Erbitux (cetuximab), Head and neck cancer 10 Published n/a June 2004 June 2008 June 2006 Iressa (gefitinib), lung cancer (non-small cell) 10 Ongoing n/a June 2004 n/a January 2009 Tysabri (natalizumab) for the treatment of multiple sclerosis 10 Published June 2006 June 2004 August 2007 September 2006 Alimta (pemetrexed) for mesothelioma 10 Published September 2004 June 2004 January 2008 April 2005 Erbitux (cetuximab) for head and neck cancer 10 Published March 2006 June 2004 June 2008 June 2006 Campto (irinotecan), colon cancer (adjuvant) 10 Ongoing n/a June 2004 n/a n/a Mabthera (rituximab) for untreated stage III or IV follicular lymphoma 11 Published August 2004 April 2005 September 2006 April 2007 Taxol (paclitaxel) for early node-positive breast cancer 11 Published March 2005 April 2005 September 2006 November 2005 Taxotere (docetaxel) for early node-positive breast cancer 11 Published March 2006 April 2005 September 2006 November 2005 Gemzar (gemcitabine) for metastatic breast cancer 11 Published September 2004 April 2005 January 2007 February 2006 Fludara (fludarabine) for chronic lymphocytic leukaemia 11 Published February 2003 April 2005 February 2007 February 2006 Alimta (pemetrexed) for the treatment of non-small cell lung cancer 11 Published n/a April 2005 August 2007 April 2006 Tarceva (erlotinib), lung cancer (non-small cell) 11 Ongoing September 2005 April 2005 n/a March 2009 Idraparinux sodium, atrial fibrillation 12 Ongoing n/a July 2006 n/a July 2006 Arava (leflunomide), psoriatic arthritis (moderate to severe) 12 Ongoing June 2004 July 2006 n/a July 2006 Idraparinux sodium, venous thromboembolism (recurrent) 12 Ongoing n/a July 2006 n/a July 2006 Herceptin (trastuzumab) for early-stage HER2-positive breast cancer 12 Published May 2006 July 2005 August 2006 December 2005 Alteplase (Actilyse) for the treatment of acute ischaemic stroke 12 Published June 2002 July 2006 June 2007 September 2006 Champix (varenicline) for smoking cessation 12 Published September 2006 July 2006 July 2007 November 2006 Humira (adalimumab) for the treatment of psoriatic arthritis 12 Published August 2005 July 2005 August 2007 September 2006 MabThera (rituximab) for the treatment of rheumatoid arthritis 12 Published July 2006 July 2005 August 2007 September 2006 Velcade (bortezomib) for multiple myeloma 12 Published April 2004 July 2005 October 2007 December 2005 Orencia (abatacept) for rheumatoid arthritis 12 Published May 2007 July 2006 April 2008 October 2006 Tyverb (lapatinib), breast cancer (advanced or metastatic) 13 Ongoing June 2008 December 2006 n/a February 2007 Cimzia (certolizumab), rheumatoid arthritis 13 Ongoing n/a December 2006 n/a December 2006 Remicade (infliximab), ulcerative colitis (acute exacerbations) 13 Ongoing February 2006 December 2006 n/a March 2007 Remicade (infliximab) for ulcerative colitis 13 Published February 2006 December 2006 April 2008 March 2007 Acomplia (rimonabant) for obesity 13 Published June 2006 December 2006 June 2008 June 2007 Baraclude (entecavir), Hepatitis B 14 Ongoing June 2006 June 2007 August 2008 September 2007 Sebivo (telbivudine), Hepatitis B 14 Ongoing April 2007 June 2007 August 2008 September 2007 Adenuric (febuxostat), hyperuricaemia 14 Ongoing April 2008 June 2007 n/a August 2007 Humira (adalimumab) for the chronic psoriasis 14 Published December 2007 June 2007 June 2008 July 2007 Ixabepilone, breast cancer (locally advanced or metastatic) 15 Ongoing n/a December 2007 n/a July 2008 Erbitux (cetuximab), colorectal cancer (first line) 15 Ongoing July 2008 December 2007 n/a January 2008 Erbitux (cetuximab), lung cancer (non-small cell) 15 Ongoing n/a December 2007 n/a October 2008 Revlimid (lenalidomide), multiple myeloma 15 Ongoing June 2007 December 2007 n/a April 2008 Xeloda (capectitabine), pancreatic cancer 15 Ongoing n/a December 2007 n/a June 2009 Pradaxa (dabigatran), venous thromboembolism 15 Ongoing March 2008 December 2007 n/a January 2008 Erbitux (cetuximab), head and neck cancer (squamous cell carcinoma) 16 Ongoing March 2006 March 2008 n/a March 2008 Effient (prasugrel), acute coronary artery syndrome 17 Ongoing n/a June 2008 n/a November 2008 Viread (tenofovir disoproxil fumarate), Hepatitis B 17 Ongoing April 2008 June 2008 n/a August 2008 Nexavar (sorafenib), hepatocellular carcinoma (advanced and metastatic) 17 Ongoing October 2007 June 2008 n/a August 2008 Orencia (abatacept), juvenile idiopathic arthritis 17 Ongoing May 2007 June 2008 n/a January 2009 Humira (adalimumab), juvenile idiopathic arthritis 17 Ongoing n/a June 2008 n/a September 2008 Sprycel (dasatinib), leukaemia (acute lymphoblastic) 17 Ongoing November 2006 June 2008 n/a July 2008 Temodal (temoazolomide), melanoma (advanced and metastatic 17 Ongoing June 2005 June 2008 n/a March 2009 Mifamurtide, Osteosarcoma 17 Ongoing n/a June 2008 n/a August 2008 Romiplostim, thrombocytompenic pupura 17 Ongoing n/a June 2008 n/a August 2008 Promacta (eltrombopag), thrombocytopenic purpura 17 Ongoing n/a June 2008 n/a March 2009 Xarelto (rivaroxaban), venous thromboembolism 17 Ongoing n/a June 2008 n/a August 2008 Azacitidine, acute myelomonocytic leukaemia and acute myeloid leukaemia 18 Ongoing n/a July 2008 n/a January 2009 Xeloda (capecitabine), advanced gastric cancer 18 Ongoing January 2008 July 2008 n/a December 2008 Methylnaltrexone, opioid-induced constipation in patients receiving palliative care 18 Ongoing n/a July 2008 n/a February 2009 Datiros (alitretinoin), severe chronic hand eczema 18 Ongoing n/a July 2008 n/a October 2008 Alimta (pemetrexed), locally advanced or metastatic non-small cell lung cancer 18 Ongoing April 2008 July 2008 n/a June 2009 Mabthera (rituximab), relapsed treatment of chronic lymphocytic leukaemia 18 Ongoing n/a July 2008 n/a September 2009 Mabthera (rituximab), chronic lymphocytic leukaemia. 18 Ongoing n/a July 2008 n/a September 2008 Sutent (sunitinib), gastrointestinal stromal tumours 18 Ongoing July 2006 July 2008 n/a August 2008 Actemra (tocilizumab), rheumatoid arthritis 18 Ongoing n/a July 2008 n/a November 2008 Hycamtin (topotecan), carcinoma of the cervix 18 Ongoing n/a July 2008 n/a December 2008 Yondelis (trabectedin), advanced metastatic soft tissue sarcoma 18 Ongoing September 2007 July 2008 n/a September 2008 Ustekinumab, moderate to severe psoriasis 18 Ongoing n/a July 2008 n/a November 2008 1 Date of marketing authorisation by European Medicines Agency (EMEA). 2 Topics before the 13 work programme were originally referred to NICE’s Multiple Technology Appraisal (MTA) programme and were transferred to the STA programme when it was introduced in August 2006. The date provided is the date the topic was originally referred to NICE as a Multiple Technology Appraisal. 3 The date NICE commenced work on the appraisal. NICE will also have carried out scoping work for the appraisal before this date.
(2) what estimate he has made of the average cost of the National Institute for Health and Clinical Excellence of undertaking a technology appraisal.
The total average direct cost to the National Institute for Health and Clinical Excellence (NICE) to develop either a multiple technology appraisal (MTA) or single technology appraisal (STA) is estimated at £100,000. The average cost to the National Coordinating Centre for Health Technology Assessment (NCCHTA), who carry out an independent assessment of the evidence in support of NICE’s appraisals, is estimated at £150,000 for an MTA and £50,000 for an STA. These estimates do not include the costs of publication, dissemination and implementation support nor do they include corporate overheads or support costs.